TriSalus Life Sciences Inc

TLSI is in an early/fragile Stage 1 base after the mid-May flush; long-term downtrend remains intact but short-term EMAs have repaired and the Bullish Pivot Point signals structural repair. Price is oscillating in a tightening range above support but is extended above rising EMAs, so the medium-term bias is bullish while execution is best deferred. The strategy is to stalk pullbacks into the rising 9/21 EMA support zone in anticipation of a breakout.

• ↑Q1 2026 revenue $8.9M drives revised FY26 guidance of $54–$57M
• ↑52% YoY revenue growth underscores strong PEDD system adoption
• ↓FDA delays postpone Trinav Advance launch, reducing H2 revenue visibility